ArticleFrontiers in pharmacology2020
Royleanone Derivatives From
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Thorough Characterization of Two Sessein Derivatives with Potential Biological Activity.Molecules (Basel, Switzerland) · 2026Article
- Extraction optimization and reactivity of 7α-acetoxy-6β-hydroxyroyleanone and ability of its derivatives to modulate PKC isoforms.Scientific reports · 2024Article
- Article
- Diterpenes Isolated from Three DifferentACS omega · 2024Article
- Exploring the Anticancer Potential of Semisynthetic Derivatives of 7α-Acetoxy-6β-hydroxyroyleanone fromInternational journal of molecular sciences · 2024Article
- Anticancer Effects of Abietane Diterpene 7α-Acetoxy-6β-hydroxyroyleanone fromMolecules (Basel, Switzerland) · 2024Article
- Coleon U, Isolated fromPharmaceutics · 2023Article
- Article
- CACS medicinal chemistry letters · 2022Article
- Anti-inflammatory activities ofFrontiers in pharmacology · 2022Article
- Self-Assembly Nanoparticles of Natural Bioactive Abietane Diterpenes.International journal of molecular sciences · 2021Article
- Preliminary Biological Activity Screening ofPharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is among the leading causes of death worldwide. One of the most challenging obstacles in cancer treatment is multidrug resistance (MDR). Overexpression of P-glycoprotein (P-gp) is associated with MDR. The growing incidence of cancer and the development of MDR drive the search for novel and more effective anticancer drugs to overcome the MDR problem. Royleanones are natural bioactive compounds frequently found in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.